Overview

Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
The main aim of this project is to establish whether ambulatory oxygen in patients with fibrotic ILD whose oxygen saturation falls ≤ 88% on a 6MWT, leads to a significant improvement in health status. The core of the project will be a four week randomised, crossover controlled trial of ambulatory oxygen used during daily activities. The optimal Oxygen flow rate is determined by titration at screening visit and administered during activity for a two-week period, compared to two weeks off oxygen.
Phase:
Phase 4
Details
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborators:
Aintree University Hospitals NHS Foundation Trust
Liverpool University Hospitals NHS Foundation Trust
National Institute for Health Research, United Kingdom